A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
← catalyst calendarNCT04970901 · readout in 224 d
Sponsored by ADC Therapeutics S.A. (industry) · ADCT — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
154actual
Sites
40
Countries
Belgium, Czechia, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-17 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-07-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- B-Cell Non-Hodgkin Lymphoma
- Relapsed B-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
- Drug: Loncastuximab Tesirine — also filed as ZYNLONTA, ADCT-402
- Drug: Polatuzumab Vedotin
- Drug: Glofitamab
- Drug: Mosunetuzumab
- Drug: Obinutuzumab
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Who Experience a Dose-Limiting Toxicity (DLT)
measured Day 1 to Day 21 of Cycle 1, where a cycle is 21 days
Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
measured Up to approximately 2 years for Arm C and 3 years for Arms E and F
Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Delay
measured Up to approximately 1 year
Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Interruption
measured Up to approximately 1 year
Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Reduction
measured Up to approximately 1 year
Number of Participants Who Experience a Clinically Significant Change from Baseline in Safety Laboratory Measurements
measured Baseline up to approximately 1 year
Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Signs
measured Baseline up to approximately 1 year
Number of Participants Who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
measured Baseline up to approximately 1 year
Number of Participants Who Experience a Clinically Significant Change from Baseline in 12-Lead Electrocardiogram (ECG) Measurements
measured Baseline up to approximately 1 year
Permalink · ADCT's whole pipeline · Catalyst calendar · Every registered study · What changed